CD28 and congenital rubella syndrome: CRS, which is a form of severe IR, can also be observed during alemtuzumab, anti-CD28 monoclonal antibody TGN1412, anti-thymocyte globulin, blinatumomab, brentuximab, dacetuzumab, muromonab-CD3, nivolumab, rituximab, and obinutuzumab treatments (referenced in [167]).